Kenneth Clark serves as general counsel to venture-backed companies and their boards of directors, primarily in the biotechnology and nanotechnology industries. Ken specializes in partnering and technology transactions, and has negotiated more than 75 major strategic alliance transactions, acquisitions, spin-outs, and related matters.
Ken was named a Northern California “Super Lawyer” in 2005, 2006 and 2007 by Law & Politics magazine. He also was recognized by Chambers and Partners in its 2005, 2006 and 2007 editions of Chambers USA: America's Leading Business Lawyers as one of the country's top biotechnology lawyers.

Dr. Gold has over 20 years of biopharmaceutical process development and manufacturing experience. He joins FAB from Human Genome Sciences (HGS) where he was Senior Vice President, Manufacturing Alliances, and Senior Vice President of Pharmaceutical Operations. Prior to joining HGS, Dr. Gold was Vice President, Process Development and Chief Scientific Officer Diosynth-RTP, Inc., where he directed the manufacturing of fifteen protein-based therapeutics, leading to IND, BLA or NDA submission and approval. Dr. Gold also held scientific and management positions in process development and manufacturing at Genencor, Genentech and Khepri Pharmaceuticals. Dr. Gold received his Ph.D. and M.S. degrees in Biochemical Engineering from the Massachusetts Institute of Technology.

James Huang, MBA, has extensive operating and business development experience through 20 years of experience in the pharmaceutical industry. He joined Vivo from Anesiva, where he served as president and previously as senior vice president of business development and commercial operations. Prior to Anesiva, he was VP Business Development and Commercial Operations at Tularik Inc prior to its acquisition by Amgen. Mr. Huang was also a product director for diabetes at SmithKline Beecham PLC (now GlaxoSmithKline), and also held various positions in product development, business development, sales and marketing, and research and development at SmithKline Beecham, Bristol-Myers Squibb, and Alza (now a Johnson & Johnson company). He received an M.B.A. from Stanford Graduate School of Business and earned a B.S. degree in Chemical Engineering at the University of California, Berkeley.

Dr. Lawlis, a 27-year biotech industry veteran, brings his broad experience in therapeutic protein development and manufacturing. Dr. Lawlis has served as President and Chief Executive Officer at Aradigm since August 2004, as President and Operating Officer from June 2003 to August 2004 and as Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999, and as Chairman 1999 to 2001, when it was sold to Diosynth, a division of Akzo Nobel. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., and Genentech, Inc. His last position at Genentech was Vice President of Process Sciences.

Dr. Mack joined Alta in 2002, and focuses on investments in biopharmaceutical products and therapeutics. David’s first Alta investment was Angiosyn (acquired by Pfizer in 2005) where he was Director and CEO. Prior to Alta, David co-founded and served as vice president of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. David was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s.David has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 23 US patents. David received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology. David holds a Bachelor of Arts in Molecular Biology from the University of California, Berkeley.

Mr. Peacock has been a Venture Partner with SV Life Sciences Advisers since May 2006. Prior to joining SV Life Sciences, Mr. Peacock held senior executive positions with a number of biotechnology, medical device, and service organizations focused on healthcare. Most recently, Mr. Peacock was CEO of The Little Clinic, a start-up medical care services company. Prior to that, Mr. Peacock served as President and Chief Executive Officer of Adolor Corporation, as President and Chief Executive Officer of Orthovita, Inc., as Executive Vice President, Chief Operating Officer of Cephalon, Inc., and Senior Vice President and CFO of Centocor, Inc. He currently serves as a member of the board of directors of several private and public biotechnology companies.

Dr. Ross joined SV Life Sciences in 2001, became a Managing Partner in 2002 and is based in San Francisco. Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH- Genentech), Vice President of Development during the development of Activase®, Nutropin®, Actimmune® and Pulmozyme®. Michael then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, (now part of Celera), MetaXen, (now part of Exelixis), CyThera (now part of Novocell) and ExSAR. Prior to joining SVLS, Michael was most recently Managing Partner in Didyma, LLC, a biotechnology management consulting firm. Michael received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed an NIH Post Doctoral Fellowship in Molecular Biology at Harvard.

Professor Swartz is a leading expert in the field of cell-free protein synthesis. Dr. Swartz holds the Leland T. Edwards Professorship in the School of Engineering at Stanford University and is a Professor in the Departments of Bioengineering and Chemical Engineering. He is a member of the National Academy of Engineering with over twenty years of industrial experience at Eli Lilly and Genentech prior to joining Stanford in 1998. Professor Swartz received his undergraduate degree in chemical engineering from the South Dakota School of Mines and his graduate degree from the Massachusetts Institute of Technology. He is an author and a co-author on numerous scientific publication dealing with protein expression and advancement of cell-free protein production technology.